Alpha Tau Medical Ltd. Ordinary Shares (DRTS)

FairStock Score: 14/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At $13.74 on 2026-10-13, Alpha Tau carries a $721.7M market cap for a clinical-stage oncology story. The business is not yet commercial: revenue growth is N/A, and FairStock's calculations show a negative P/E of -12.96 and a P/B of 28.62. That P/B is the rub. I am asked to pay nearly 29 times book for a company with a ROE of -141.68% and ROCE of -25.71%. Graham would call that speculative, not defensive. The balance sheet has D/E of 0.34, so leverage alone is not the problem. But Piotroski F-Score 3/9 and only 0 years of filed results—no Lynch category—tell me there is little financial history to underwrite. The Altman Z-Score of 2.97 is not distressed, yet it does not offset negative returns. The potential moat rests on Alpha DaRT's diffusing alpha-emitters radiation therapy, in trials for skin, oral, pancreatic, prostate, lung, liver, and breast cancers, plus a strategic collaboration. That is a broad platform, but breadth in early-stage biotech is not a moat; it is a promise. The 52-week range of $3.43 to $15.79 shows the market's mood swings. Growth is entirely event-driven: trial data, approvals, partnership milestones. Until there is commercial revenue and positive returns, intrinsic value is hard to calculate. I would wait for evidence of durable economics rather than pay a premium for hope.

In plain English: Alpha Tau Medical is a clinical-stage company developing a radiation therapy for solid tumors. It has no commercial product yet and loses money, with deeply negative returns on its capital. At $13.74, the stock looks expensive compared with its earnings and accounting value, so the price depends heavily on future trial success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer